Harvard Medical School Study Validates Opportunity For Urigen Pharmaceuticals’ Platform Technology To Develop Treatment For Painful Bladder Syndrome

Urigen Pharmaceuticals, Inc. (OTC BB: URGP), a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced that a recent epidemiological study conducted by researchers at the Harvard Medical School has demonstrated that Painful Bladder Syndrome (PBS) is a commonly occurring disorder amongst women, further supporting the Company’s focus on developing treatments for the condition.

More: continued here

Filed under: Pain / Anesthetics on March 31st, 2009